Cefiderocol resistance genomics in sequential chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the outstanding capacity of P. aeruginosa for developing antimicrobial resistance is for seen in the extraordinary versatility of is vast mutational resistome, not only dependent on the exposure to a specific antibiotic but conditioned by simultaneous or even previous exposures to other [17,18].”
From Mechanisms of antibiotic resistance in Pseudomonas aeruginosa biofilms (2023) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02724-0 · Cited by 16,316
Research works printed but not linked: 31
- Oliver, 2000, High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection, Science, 288, 1251, 10.1126/science.288.5469.1251 · DOI · Paper page
- López-Causapé, 2018, The versatile mutational resistome of Pseudomonas aeruginosa, Front Microbiol, 9, 685, 10.3389/fmicb.2018.00685 · DOI · Paper page
- Tabak, 2019, Incremental clinical and economic burden of suspected respiratory infections due to multi-drug-resistant Pseudomonas aeruginosa in the United States, J Hosp Infect, 103, 134, 10.1016/j.jhin.2019.06.005 · DOI
- Tacconelli, 2018, Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis, Lancet Infect Dis, 18, 318, 10.1016/S1473-3099(17)30753-3 · DOI · Paper page
- Horcajada, 2019, Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections, Clin Microbiol Rev, 32, 10.1128/CMR.00031-19 · DOI · Paper page
- Del Barrio-Tofiño, 2020, Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update, Int J Antimicrob Agents, 56, 10.1016/j.ijantimicag.2020.106196 · DOI · Paper page
- Oliver, 2015, The increasing threat of Pseudomonas aeruginosa high-risk clones, Drug Resist Updat, 21–22, 41, 10.1016/j.drup.2015.08.002 · DOI · Paper page
- Parkins, 2018, Epidemiology, biology, and impact of clonal Pseudomonas aeruginosa infections in cystic fibrosis, Clin Microbiol Rev, 31, 10.1128/CMR.00019-18 · DOI · Paper page
- Ciofu, 2015, Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients, Adv Drug Deliv Rev, 85, 7, 10.1016/j.addr.2014.11.017 · DOI · Paper page
- Schick, 2018, Rapid diversification of Pseudomonas aeruginosa in cystic fibrosis lung-like conditions, Proc Natl Acad Sci U S A, 115, 10714, 10.1073/pnas.1721270115 · DOI
- Mena, 2008, Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation, J Bacteriol, 190, 7910, 10.1128/JB.01147-08 · DOI · Paper page
- Rossi, 2021, Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis, Nat Rev Microbiol, 19, 331, 10.1038/s41579-020-00477-5 · DOI · Paper page
- Canton, 2022, Treatment of carbapenem-resistant Pseudomonas aeruginosa infections: a case for cefiderocol, Expert Rev Anti Infect Ther, 20, 1077, 10.1080/14787210.2022.2071701 · DOI
- Sato, 2019, Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin, Clin Infect Dis, 69, S538, 10.1093/cid/ciz826 · DOI · Paper page
- Marvig, 2015, Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis, Nat Genet, 47, 57, 10.1038/ng.3148 · DOI · Paper page
- López-Causapé, 2017, Evolution of the Pseudomonas aeruginosa mutational resistome in an international Cystic Fibrosis clone, Sci Rep, 7, 5555, 10.1038/s41598-017-05621-5 · DOI · Paper page
- Cortes-Lara, 2021, Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis, Clin Microbiol Infect, 27, 1631, 10.1016/j.cmi.2021.05.011 · DOI
- López-Causapé, 2013, Clonal dissemination, emergence of mutator lineages and antibiotic resistance evolution in Pseudomonas aeruginosa cystic fibrosis chronic lung infection, PLoS One, 8, 10.1371/journal.pone.0071001 · DOI
- García-Castillo, 2012, Emergence of a mutL mutation causing multilocus sequence typing-pulsed-field gel electrophoresis discrepancy among Pseudomonas aeruginosa isolates from a cystic fibrosis patient, J Clin Microbiol, 50, 1777, 10.1128/JCM.05478-11 · DOI
- Vettoretti, 2009, Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients, Antimicrob Agents Chemother, 53, 1987, 10.1128/AAC.01024-08 · DOI
- Fraile-Ribot, 2018, Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa, J Antimicrob Chemother, 73, 658, 10.1093/jac/dkx424 · DOI · Paper page
- Simner, 2021, Cefiderocol activity against clinical Pseudomonas aeruginosa isolates exhibiting ceftolozane-tazobactam resistance, Open Forum Infect Dis, 8, 10.1093/ofid/ofab311 · DOI
- Wunderink, 2021, Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial, Lancet Infect Dis, 21, 213, 10.1016/S1473-3099(20)30731-3 · DOI · Paper page
- Bassetti, 2021, Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial, Lancet Infect Dis, 21, 226, 10.1016/S1473-3099(20)30796-9 · DOI · Paper page
- Nordmann, 2022, Mechanisms of reduced susceptibility to cefiderocol among isolates from the CREDIBLE-CR and APEKS-NP clinical trials, Microb Drug Resist, 28, 398, 10.1089/mdr.2021.0180 · DOI
- Tümmler, 2005, Pyoverdine receptor: a case of positive Darwinian selection in Pseudomonas aeruginosa, J Bacteriol, 187, 3289, 10.1128/JB.187.10.3289-3292.2005 · DOI
- Luscher, 2018, TonB-dependent receptor repertoire of Pseudomonas aeruginosa for uptake of siderophore-drug conjugates, Antimicrob Agents Chemother, 62, 10.1128/AAC.00097-18 · DOI · Paper page
- Ito, 2017, In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria, Antimicrob Agents Chemother, 62
- Klein, 2022, Rapid development of cefiderocol resistance in carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cirA, Clin Infect Dis, 74, 905, 10.1093/cid/ciab511 · DOI
- Werth, 2022, Evolution of cefiderocol resistance in Stenotrophomonas maltophilia using in vitro serial passage techniques, JAC Antimicrob Resist, 4, dlac011, 10.1093/jacamr/dlac011 · doi:10.1093/jacamr/dlac011
- McElheny, 2021, In vitro evolution of cefiderocol resistance in an NDM-producing Klebsiella pneumoniae due to functional loss of cirA, Microbiol Spectr, 9, 10.1128/Spectrum.01779-21 · DOI
Cited by
Mechanisms of antibiotic resistance in Pseudomonas aeruginosa biofilms
Fernández-Billón, M., Llambías-Cabot, A. E., Jordana-Lluch, E., Oliver, A., & Macià, M. D. (2023) · Biofilm · doi:10.1016/j.bioflm.2023.100129 · Cited by 170
Self-citation
Metadata
- Authors
- López-Causapé, C., Maruri-Aransolo, A., Gomis-Font, M. A., Penev, I., Castillo, M. G., Mulet, X., de Dios Caballero, J., Campo, R. D., Cantón, R., & Oliver, A.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2023-04
- Volume
- 29
- Issue
- 4
- Pages
- 538.e7-538.e13
- ISSN
- 1198-743X
- Cited by
- 34
- References
- 1
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 387 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.